Cipla Gains 2%: USFDA Clears InvaGen New York Plant
💊 CIPLA rose about 2.1% to ₹1,417.50 on 18 Nov 2026, even as the Nifty fell 0.63% on profit booking. The trigger: the USFDA has classified the recent inspection of its US subsidiary InvaGen's New York facility as "No Action Indicated" (NA…





















